Amgen - Biotech Market Share Report

Amgen market share graphic featuring Enbrel, Arenesp, Epogen, Neulasta and NeupogenCompany: Amgen
2007 Sales: $15.9 billion
Market share: 21.3$
CAGR: 27%

What Amgen has: Amgen has five of the 22 biotech blockbusters currently on the market--tied only with Roche. Marketed by Amgen and Wyeth, Enbrel tops this list as the world's bestselling biologic. The drug is indicated for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis and moderate to severe plaque psoriasis. Enbrel, which competes with Remicade and Humira, brought in $5.2 billion in sales in 2007.

Amgen saw sales of anemia drugs Arenesp and Epogen take a hit last year when the two garnered black box warnings for heart and vascular problems at high doses. Still, the second and eighth ranked blockbusters racked up $4.4 billion and $2.9 billion, respectively. Neulasta and Neupogen (which treat a lack of certain white blood cells caused by cancer and chemo) round out the company's blockbusters.

What to watch for: Amgen's next big up-and-coming drug is, of course, the osteoporosis treatment Denosumab. The drug has already been submitted for FDA review and, if approved, could bring in $2 billion to $3 billion in sales a year.

Amgen - Biotech Market Share Report
Read more on

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.